Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3225 SEK | -0.15% | +8.22% | -96.78% |
22/05 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
16/05 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-96.78% | 47.48M | |
+52.28% | 59.28B | |
+41.76% | 40.94B | |
-5.80% | 40.17B | |
-5.56% | 28.69B | |
+10.76% | 26.63B | |
-21.08% | 18.89B | |
+30.01% | 12.46B | |
+1.44% | 12.42B | |
+26.90% | 12.26B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Transcript : Xbrane Biopharma AB - Special Call